<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="308426">
  <stage>Registered</stage>
  <submitdate>6/03/2010</submitdate>
  <approvaldate>4/05/2010</approvaldate>
  <actrnumber>ACTRN12610000353099</actrnumber>
  <trial_identification>
    <studytitle>low dose Aspirin for improving fatigue of multiple sclerosis patients</studytitle>
    <scientifictitle>assessment of effects of low dose aspirin in treatment of fatigue in patients with multiple sclerosis</scientifictitle>
    <utrn>nil</utrn>
    <trialacronym>nil</trialacronym>
    <secondaryid>nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Multiple sclerosis</healthcondition>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Multiple sclerosis</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>tablet aspirin orally 80 mg/day once a day for 8 weeks</interventions>
    <comparator>oral tablet microcellulose 80 mg one a day for 8 weeks</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>fatigue impact scale</outcome>
      <timepoint>8 weeks following randomisation</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>depression(Beck 2 score)</outcome>
      <timepoint>8 weeks following randomisation</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>nil</outcome>
      <timepoint>nil</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-known cases of relapsing-remitting ,secondary progressive,primary progressive Multiple sclerosis
-ability to walk at least 100 meters without help</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>60</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-co-existence of cardiac, respiratory, metabolic disease
-exacerbation of disease in the recent month
-consuming drugs affecting neurological system in 2 weeks before start point
-major depression</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>1/05/2010</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>110</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Iran, Islamic Republic Of</country>
      <state>tehran</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>nabavi ,seyed masoud</primarysponsorname>
    <primarysponsoraddress>Mostafa Khomeini Hospital
Vesal St., Italia St.
Tehran
Iran
Postal/ZIP 141665185</primarysponsoraddress>
    <primarysponsorcountry>Iran, Islamic Republic Of</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>cinnagen company</fundingname>
      <fundingaddress>cinnagen company
5th floor,No 14,Azimi St.
phase 1 ,shahrak ekbatan
Tehran
Iran
Postal/ZIP 1393833161</fundingaddress>
      <fundingcountry>Iran, Islamic Republic Of</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>shahed</fundingname>
      <fundingaddress>Shahed University 
Opposite Holy Shrine of Imam Khomeini
Kalij Fars Expressway
Tehran
Postal/ZIP 3319118651</fundingaddress>
      <fundingcountry>Iran, Islamic Republic Of</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Multiple sclerosis (MS) is one of disabling diseases in youngs . Fatigue is one of the most common complications of multiple sclerosis, reported in 70 to 100 percent of patients. Pathophysiology of this symptom has not fully understood in this disease, yet.
Aspirin (1300mg/daily) was used for relieving this complication for the first time by Wingerchuk,D.M(2005) and reported to had statistically meaningful  comparing placebo. But high dose aspirin has multiple gastrointestinal and cardiovascular complications, limiting its use.
In this study low dose aspirin (80mg/daily) will be compared with placebo in treatment of fatigue in 110 MS patients in hope to reduce high dose aspirin complications.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>ethics committee of shahed university</ethicname>
      <ethicaddress>Shahed University 
Opposite Holy Shrine of Imam Khomeini
Kalij Fars Expressway
Tehran
Iran
Postal/ZIP 3319118651</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Iran, Islamic Republic Of</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Nabavi, seyed masoud</name>
      <address>Mostafa Khomeini Hospital
Vesal St., Italia St.
Tehran
Iran
Postal/ZIP 141665185</address>
      <phone>+982188963122</phone>
      <fax />
      <email>massood@yahoo.com</email>
      <country>Iran, Islamic Republic Of</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>pourfarzam, shahryar</name>
      <address>Mostafa Khomeini Hospital
Vesal St., Italia St.
Tehran
Iran
Postal/ZIP 141665185</address>
      <phone>+982188963122</phone>
      <fax>+982188963122</fax>
      <email>sh.pourfarzam@gmail.com</email>
      <country>Iran, Islamic Republic Of</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>pourfarzam, shahryar</name>
      <address>Mostafa Khomeini Hospital
Vesal St., Italia St.
Tehran
Iran
Postal/ZIP 141665185</address>
      <phone>+982188963122</phone>
      <fax>+982188963122</fax>
      <email>sh.pourfarzam@gmail.com</email>
      <country>Iran, Islamic Republic Of</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>